Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Staar Surgical ( (STAA) ) is now available.
On January 6, 2026, STAAR Surgical reported that preliminary voting results from a special meeting of stockholders showed the company did not receive sufficient shareholder support to approve its previously announced merger agreement with Alcon Research. As a result, STAAR intends to terminate the merger agreement without any termination fee due from either party, and will continue as an independent, publicly traded company on Nasdaq under the ticker STAA, with management reaffirming its strategy to pursue profitable sales growth, drive distribution efficiencies, and expand global adoption of its EVO ICL technology as it seeks to maximize long-term shareholder value.
The most recent analyst rating on (STAA) stock is a Hold with a $30.75 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
Staar Surgical’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s financial challenges and bearish technical indicators weigh heavily on the score. The valuation is also weak due to negative earnings. However, the potential merger with Alcon offers a positive outlook, though it is not included in the weighted score due to the exclusion of corporate events.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company (NASDAQ: STAA) is a global leader in implantable phakic intraocular lenses (ICLs), offering the EVO family of Implantable Collamer Lenses for vision correction that reduce or eliminate dependence on glasses or contact lenses. Dedicated solely to ophthalmic surgery since 1982, the company designs, develops, manufactures, and markets advanced ICLs made from its proprietary biocompatible Collamer material, has sold more than 3 million lenses in over 75 countries, and operates research, development, manufacturing, and packaging facilities in California and Switzerland from its headquarters in Lake Forest, California.
Average Trading Volume: 1,203,501
Technical Sentiment Signal: Sell
Current Market Cap: $1.19B
See more data about STAA stock on TipRanks’ Stock Analysis page.